-
公开(公告)号：US12122816B2
公开(公告)日：2024-10-22
申请号：US18347246
申请日：2023-07-05
IPC分类号： C07K14/575 , A61K38/00 , A61P3/04
CPC分类号： C07K14/575 , A61P3/04 , A61K38/00
摘要： This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：US12084485B2
公开(公告)日：2024-09-10
申请号：US17553381
申请日：2021-12-16
CPC分类号： C07K14/605 , A61K9/0004 , A61K38/26 , A61P1/16 , A61P3/04
摘要： This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：US20240166708A1
公开(公告)日：2024-05-23
申请号：US18347246
申请日：2023-07-05
IPC分类号： C07K14/575 , A61P3/04
CPC分类号： C07K14/575 , A61P3/04 , A61K38/00
摘要： This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：US11739134B2
公开(公告)日：2023-08-29
申请号：US17233111
申请日：2021-04-16
IPC分类号： C07K14/575 , A61P3/04 , A61K38/00
CPC分类号： C07K14/575 , A61P3/04 , A61K38/00
摘要： This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：US11840559B2
公开(公告)日：2023-12-12
申请号：US17538507
申请日：2021-11-30
发明人： William Blackwell , Ved P. Srivastava , Mark A. Paulik , Andrew Young , Robert Neil Hunter, III , Steven Thomas Dock
CPC分类号： C07K14/605 , A61K9/0004 , A61K38/26 , C07K14/00 , A61M5/14276 , A61M31/002 , A61M2005/14513
摘要： This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
-
公开(公告)号：US11214607B2
公开(公告)日：2022-01-04
申请号：US16667502
申请日：2019-10-29
发明人： William Blackwell , Ved P. Srivastava , Mark A. Paulik , Andrew Young , Robert Neil Hunter, III , Steven Thomas Dock
摘要： This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
-
公开(公告)号：US12018059B2
公开(公告)日：2024-06-25
申请号：US16598915
申请日：2019-10-10
IPC分类号： C07K14/575 , A61K9/00 , A61K38/00 , A61P3/04 , A61P3/10
CPC分类号： C07K14/575 , A61K9/0004 , A61K9/0019 , A61P3/04 , A61P3/10 , A61K38/00
摘要： This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1/2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.
-
公开(公告)号：US20230063420A1
公开(公告)日：2023-03-02
申请号：US17553381
申请日：2021-12-16
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04 , A61K9/00 , A61P1/16
摘要： This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
-
公开(公告)号：US20200299350A1
公开(公告)日：2020-09-24
申请号：US16667502
申请日：2019-10-29
发明人： William Blackwell , Ved P. Srivastava , Mark A. Paulik , Andrew Young , Robert Neil Hunter, III , Steven Thomas Dock
IPC分类号： C07K14/605 , C07K14/00 , A61K38/26 , A61K9/00
摘要： This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
-
公开(公告)号：US20220332781A1
公开(公告)日：2022-10-20
申请号：US17538507
申请日：2021-11-30
发明人： William Blackwell , Ved P. Srivastava , Mark A. Paulik , Andrew Young , Robert Neil Hunter, III , Steven Thomas Dock
IPC分类号： C07K14/605 , C07K14/00 , A61K38/26 , A61K9/00
摘要： This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.023 秒)
